Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

Supira Medical 获得 1.2 亿美元超额认购的 E 轮融资，并完成了美国 SUPPORT I 早期可行性研究的入组工作。

LOS GATOS, Calif., March 26, 2025-- Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelerate the company's mission of transforming the percutaneous ventricular assist device (pVAD) market.

加利福尼亚州洛斯加托斯，2025年3月26日——Supira Medical, Inc.（Supira），一家处于临床阶段的Shifamed投资组合公司，今天宣布成功完成了一轮超额认购的E轮融资，筹集了1.2亿美元，以加速公司转变经皮心室辅助装置（pVAD）市场的使命。

The round was led by new investors Novo Holdings and Qatar Investment Authority (QIA), along with participation from two undisclosed strategic investors. Existing investors participated as well, including Cormorant Asset Management and The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures.

本轮融资由新投资者 Novo Holdings 和卡塔尔投资局 (QIA) 领投，另有两家未披露的战略投资者参与。现有投资者也参与其中，包括 Cormorant Asset Management、The Capital Partnership (TCP)、415 Capital、AMED Ventures、PA MedTech VC 基金和 Unorthodox Ventures。

Funds will be used to expand Supira's clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). This clinical expansion includes the SUPPORT II U.S. Pivotal Study for HRPCI, which will be used to seek FDA PMA approval..

资金将用于扩展 Supira 针对高风险经皮冠状动脉介入治疗 (HRPCI) 和心源性休克 (CS) 的临床项目。这一临床扩展包括用于 HRPCI 的 SUPPORT II 美国关键研究，该研究将用于寻求 FDA 的 PMA 批准。

'We are grateful for the continued confidence and support from our current investors and delighted to welcome new world-class investors to this financing consortium,' commented Dr. Nitin Salunke, President and CEO of Supira Medical. 'This significant capital raise underscores the team's tremendous progress as we look forward to exciting opportunities ahead of us to improve clinical outcomes for both HRPCI and cardiogenic shock patients.'.

“我们感谢现有投资者的持续信任与支持，并很高兴欢迎新的世界级投资者加入本轮融资财团，”Supira Medical 总裁兼首席执行官尼丁·萨鲁恩克博士表示。“此次重要的资本募集彰显了团队的巨大进展，我们期待未来令人兴奋的机会，为高危经皮冠状动脉介入治疗（HRPCI）和心源性休克患者改善临床结果。”

Additionally, Supira welcomes Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors. 'We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients,' stated Dr.

此外，Supira欢迎Novo Holdings美国合伙人克里斯托弗·沈博士加入其董事会。沈博士表示：“我们认为，下一代心室辅助装置在促进心肌恢复和改善高风险经皮冠状动脉介入治疗（HRPCI）和心源性休克（CS）患者的外周器官灌注方面存在巨大的未满足需求。”

Shen. 'The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of interventional heart failure, and we are pleased with their excellent progress bringing this therapy closer to market.'.

沈：“Supira 团队已经建立了强大的临床基础，以进一步验证其先进的低调高流量技术平台在心力衰竭介入治疗的两个重要领域中的应用，我们对其取得的出色进展感到满意，这将使该疗法更接近市场。”

The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study (EFS), enrolling a total of 15 patients across four clinical sites. The prospective, single-arm clinical study evaluated the safety and feasibility of Supira's innovative pVAD in patients undergoing HRPCI.

该公司最近完成了其美国SUPPORT I早期可行性研究（EFS）的患者招募，总共在四个临床站点招募了15名患者。这项前瞻性、单臂临床研究评估了Supira创新的pVAD在进行高风险经皮冠状动脉介入治疗（HRPCI）患者中的安全性和可行性。

pVADs are important for supporting cardiovascular function during HRPCI, particularly in patients with complex coronary anatomy, compromised hemodynamics, and multiple comorbidities. They are also used in cardiogenic shock, a high-mortality condition where the heart is too weak to pump sufficient blood to vital organs, usually resulting from a heart attack or heart failure.

pVADs 在 HRPCI 期间对支持心血管功能非常重要，尤其是在冠状动脉解剖复杂、血流动力学受损以及有多重合并症的患者中。它们也用于心源性休克，这是一种高死亡率的情况，心脏过于虚弱，无法将足够的血液泵送到重要器官，通常由心脏病发作或心力衰竭引起。

The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world..

Supira系统是一种研究性设备，尚未获准在美国或世界任何地方销售。

Piper Sandler acted as exclusive financial advisor and Sidley Austin LLP acted as legal counsel to Supira Medical in this transaction.

Piper Sandler 在此次交易中担任 Supira Medical 的独家财务顾问，Sidley Austin LLP 担任法律顾问。

About Supira Medical, Inc.

关于Supira Medical公司

Supira Medical, a clinical-stage Shifamed portfolio company, is focused on the development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To date, the Supira System has benefited 85 HRPCI patients. To learn more about Supira Medical, please visit www.supiramedical.com..

Supira Medical 是一家临床阶段的 Shifamed 旗下公司，专注于开发用于高危患者进行介入手术及经历心源性休克的下一代 pVAD。迄今为止，Supira 系统已使 85 名 HRPCI 患者受益。如需了解更多信息，请访问 www.supiramedical.com。

About Novo Holdings

关于诺和控股

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

诺和控股是一家控股和投资公司，负责管理诺和诺德基金会的资产和财富。诺和控股的宗旨是通过为诺和诺德基金会的资产创造有吸引力的长期回报，改善人民健康及社会和地球的可持续性。

.

。

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor.

完全由诺和诺德基金会拥有的诺和控股是诺和诺德公司和诺维尼斯公司（诺维信公司）的控股股东，并管理着一个以长期回报为目标的投资组合。除了管理广泛的股票、债券、房地产、基础设施和私募股权资产外，诺和控股还是世界领先的生命科学领域投资者。

Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. .

通过其种子、风险、成长、亚洲、行星健康和主要投资团队，Novo Holdings投资于生命科学领域各个发展阶段的公司。

As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

截至 2023 年年底，诺和控股的总资产为 1490 亿欧元。www.novoholdings.dk

About Qatar Investment Authority

关于卡塔尔投资局

QIA is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar..

卡塔尔投资局（QIA）是卡塔尔国的主权财富基金。QIA成立于2005年，旨在投资和管理国家储备基金。QIA是全球规模最大、最活跃的主权财富基金之一。QIA在广泛的资产类别和地区进行投资，并与全球领先的机构合作，以构建一个多元化、具有长期视角的全球投资组合，致力于实现可持续回报并为卡塔尔国的繁荣作出贡献。

Media contact: media@qia.qa

媒体联系：media@qia.qa

About Shifamed, LLC.

关于Shifamed有限责任公司。

Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to live longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com..

Shifamed 由连续创业者 Amr Salahieh 创立，是一个高度专业化的医疗创新中心，专注于开发加速上市时间、降低风险、增加影响并引领通往患者能够更长寿、更健康生活的世界的解决方案。如需了解更多关于 Shifamed 的信息，请访问 www.shifamed.com。

Contact:

联系人：

Media Contact:

媒体联系人：

Craig Brandli

克雷格·布兰德利

VP of Marketing

营销副总裁

craig@supiramedical.com

克雷格@supiramedical.com